# Giant Cell Arteritis

Treat suspected giant cell arteritis immediately when ischemic manifestations are present, while rapidly confirming cranial and large-vessel disease with vascular imaging and/or temporal artery biopsy.

**Clinical question:** How should clinicians urgently evaluate, confirm, treat, and monitor suspected giant cell arteritis?

Updated: 2026-08-21T01:50:55.015844+00:00

## What matters in practice
- GCA is a medical emergency because delayed recognition can result in sudden irreversible visual loss or stroke; start high-dose glucocorticoids when clinical suspicion is sufficient, rather than awaiting confirmatory testing.[10][11][20]
- Jaw claudication, diplopia, and a clinically abnormal temporal artery increase the likelihood of a positive vascular ultrasound and/or temporal artery biopsy.[1]
- Use a confirmatory test—temporal artery biopsy, temporal artery ultrasound, or both—rather than diagnosis from symptoms and inflammatory markers alone.[6][13]
- Temporal and axillary artery ultrasound is a first-line imaging strategy in contemporary practice; a noncompressible halo sign in a patient with high pretest probability may obviate temporal artery biopsy.[3]
- A negative temporal artery biopsy does not exclude GCA: pooled biopsy sensitivity is 61%, whereas specificity is 98% in patients with a clinical diagnosis.[22]
- Assess for extracranial large-vessel involvement at diagnosis and during follow-up because aortic and branch-vessel disease may cause limb claudication, chest or back pain, stenosis, and aneurysm.[10][20]

## Identify ischemic GCA before diagnostic confirmation

Prioritize threatened vision and cerebrovascular ischemia over diagnostic sequencing.

In adults aged 50 years or older with suspected GCA, immediately ask about transient or persistent monocular visual loss, diplopia, jaw claudication, scalp or tongue ischemia, and focal neurologic symptoms. Cranial GCA can cause sudden permanent visual loss and stroke, and the relevant cranial arterial territories include the temporal, ophthalmic, posterior ciliary, and vertebral arteries.[1][9][10][12]

Begin high-dose glucocorticoids once GCA is suspected; do not delay therapy for biopsy or imaging. Prompt steroid treatment can prevent further visual loss, although visual loss can occur at treatment initiation and during glucocorticoid tapering.[11][20][21]

Escalate same day for ophthalmologic assessment when visual symptoms, diplopia, or suspected anterior ischemic optic neuropathy is present, and involve rheumatology urgently to coordinate disease confirmation and glucocorticoid-sparing therapy. Established ischemic events, including contralateral visual loss from anterior ischemic optic neuropathy, identify patients at higher subsequent risk of permanent visual loss.[11]
- Treat as cranial ischemic GCA: new visual symptoms, diplopia, jaw claudication, tongue or scalp necrosis, or focal neurologic deficit.[1][9][10]
- Do not use normal or low inflammatory markers to rule out cranial GCA; markers may be low to normal in cranial-only disease.[6]
- Do not await temporal artery biopsy before starting glucocorticoids when the clinical consequences of delay include irreversible ischemia.[11][20][21]

*Clinical features that change urgency and diagnostic yield in suspected GCA.[1][6][10][11]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Visual loss, transient visual symptoms, or diplopia | Potential cranial ischemia with risk of permanent visual loss.[10][11] | Start high-dose glucocorticoids immediately; obtain urgent ophthalmologic and rheumatology assessment while arranging confirmation.[11][20][21] |
| Jaw claudication or abnormal temporal artery | Raises likelihood that vascular ultrasound and/or temporal artery biopsy will be positive for GCA.[1] | Obtain expedited temporal artery ultrasound and/or biopsy; do not defer treatment if overall suspicion is high.[1][6][11] |
| Normal inflammatory markers | Does not exclude cranial-only GCA.[6] | Maintain diagnostic evaluation when ischemic cranial features are present; use vascular imaging and/or biopsy.[6][13] |
| Limb claudication, chest pain, or back pain | Suggests extracranial large-vessel involvement, stenosis, or aneurysmal disease.[10] | Add large-vessel imaging and assess for aortic and major branch-vessel complications.[10][20] |

## Confirm GCA with vascular testing matched to phenotype

Use clinical probability to select and interpret imaging and biopsy.

Obtain a confirmatory test in suspected GCA: temporal artery biopsy (TAB), temporal artery ultrasound, or both. A diagnosis based only on symptoms, examination, and inflammatory markers risks overdiagnosis because presenting symptoms may be nonspecific and inflammatory markers are not specific for GCA.[6][13]

For a cranial phenotype, perform vascular ultrasonography of the temporal and axillary arteries where expertise is available. EULAR-oriented practice places temporal and axillary ultrasound as first-line imaging; in a patient with high pretest probability, a noncompressible halo sign can replace TAB.[3] Ultrasound is more sensitive but less specific than TAB, making pretest probability and image quality consequential when interpreting a positive result.[6]

Use TAB when ultrasound is unavailable, nondiagnostic, discordant with clinical probability, or when tissue confirmation will materially alter long-term immunosuppression decisions. TAB has pooled sensitivity of 61% and specificity of 98%; therefore, a positive result is highly confirmatory, but a negative result should prompt reassessment for imaging-supported cranial or extracranial disease rather than automatic discontinuation of treatment.[22]

Do not apply the 2022 ACR/EULAR classification criteria as a stand-alone diagnostic rule. They were developed to classify research populations after medium- or large-vessel vasculitis has been identified; in a real-world suspected-GCA cohort, diagnostic use retained high sensitivity but had lower specificity, and patients without cranial manifestations could fail to meet criteria despite typical imaging abnormalities outside the scored vascular territories.[3][15]
- Document temporal artery abnormalities on examination and ask specifically about jaw claudication and diplopia because these findings enrich the likelihood of a positive ultrasound and/or TAB.[1]
- Image axillary arteries with the temporal arteries to improve assessment for large-vessel GCA.[3]
- When TAB is negative but clinical concern remains high, pursue vascular imaging and reassess competing diagnoses rather than treating biopsy as an exclusion test.[3][22]

### When to expand beyond cranial imaging

Evaluate for large-vessel GCA when constitutional or polymyalgic symptoms occur without a dominant cranial syndrome, when arm or limb claudication is present, or when chest or back pain raises concern for aortic disease. CT angiography, MR angiography, FDG-PET/CT, and MRI are among imaging modalities incorporated into contemporary GCA assessment; their use is particularly relevant for extracranial aortic and supra-aortic branch involvement.[3][10][13]

Large-vessel imaging may identify disease in more than half of suspected GCA cases in some contemporary cohorts, and imaging evidence of large-vessel GCA has been reported in 22% to 83% of newly diagnosed patients. This phenotypic breadth explains why isolated cranial testing can miss clinically important disease.[3][10]

*Diagnostic test selection in suspected GCA.[3][6][13][22]*

| Test or framework | Best use | Interpretive limitation |
| --- | --- | --- |
| Temporal and axillary artery ultrasound | First-line vascular imaging for suspected cranial GCA; a noncompressible halo sign may replace TAB when pretest probability is high.[3] | Ultrasound is more sensitive but less specific than TAB; performance depends on appropriate interpretation in clinical context.[6] |
| Temporal artery biopsy | Tissue confirmation when imaging is unavailable, inconclusive, or discordant with clinical probability.[6][13] | Pooled sensitivity is 61%; a negative biopsy cannot by itself exclude GCA. Specificity is 98%.[22] |
| CTA, MRA, MRI, or FDG-PET/CT | Evaluate suspected extracranial large-vessel disease involving the aorta or major branches.[3][10][13] | These studies complement rather than replace assessment for cranial ischemic manifestations.[10][20] |
| 2022 ACR/EULAR classification criteria | Research classification after a diagnosis of medium- or large-vessel vasculitis is under consideration.[3][15] | Not a stand-alone diagnostic exclusion tool; specificity fell to 70.3% in one suspected-GCA cohort.[15] |

## Separate cranial, large-vessel, and polymyalgic presentations

Phenotype determines the vascular territory to test and the complications to surveil.

Classify the presentation clinically as cranial GCA, extracranial large-vessel GCA, polymyalgia rheumatica-associated disease, or overlap. These phenotypes frequently overlap: cranial GCA is the most commonly diagnosed form, whereas extracranial disease generally involves the aorta and larger supra-aortic branches and may coexist with polymyalgic or constitutional symptoms.[9][10]

A cranial-predominant syndrome is supported by new headache, abnormal temporal artery findings, jaw claudication, diplopia, or ischemic ocular symptoms; among these, jaw claudication, diplopia, and an abnormal temporal artery are particularly useful discriminators for positive vascular testing.[1] Occult cranial GCA can present without systemic symptoms, so absence of fever, weight loss, or polymyalgic symptoms should not lower concern enough to defer evaluation in a patient with ocular ischemia.[6]

A large-vessel-predominant syndrome should be considered with limb claudication, chest pain, back pain, or imaging evidence of aortic or branch-vessel inflammation. The clinically important downstream lesions are stenosis and aneurysm formation, including thoracic and abdominal aortic aneurysms; direct imaging is needed because cranial symptoms alone do not define the full vascular burden.[10][20]

Before committing to prolonged treatment, actively reassess mimics when the clinical pattern, inflammatory markers, and imaging are discordant. In a suspected-GCA cohort, polymyalgia rheumatica and nonvasculitic ophthalmologic disorders accounted for substantial portions of patients meeting the 2022 classification score despite not having GCA, underscoring that a classification score cannot substitute for diagnostic adjudication.[15]
- Cranial pattern: prioritize temporal/axillary ultrasound or TAB and immediate ischemic-risk treatment.[1][3][6]
- Large-vessel pattern: add CTA, MRA, MRI, or FDG-PET/CT to define aortic and branch-vessel involvement.[3][10][13]
- Discordant pattern: revisit nonvasculitic ophthalmologic disease and PMR without vasculitis rather than using classification criteria as the final diagnostic arbiter.[15]

*Actionable GCA phenotypes and their diagnostic consequences.[1][3][6][10]*

| Predominant pattern | Key discriminator | Testing priority | Complication focus |
| --- | --- | --- | --- |
| Cranial GCA | Jaw claudication, diplopia, abnormal temporal artery, or visual ischemic symptoms.[1] | Temporal and axillary artery ultrasound; TAB when needed for confirmation.[3][6] | Sudden permanent visual loss and stroke.[9][10] |
| Large-vessel GCA | Limb claudication, chest pain, back pain, or aortic/branch-vessel imaging abnormality.[10] | CTA, MRA, MRI, or FDG-PET/CT to assess aorta and major branches.[3][10][13] | Stenosis and thoracic or abdominal aortic aneurysm.[10] |
| PMR-associated or overlap disease | Polymyalgic symptoms with or without cranial or vascular manifestations.[10] | Screen for cranial ischemic features and obtain vascular imaging when GCA remains plausible.[3][10] | Missed cranial or large-vessel disease when symptoms are attributed to PMR alone.[10][15] |

## Treat urgently, then monitor for relapse and structural vascular disease

Separate immediate ischemia prevention from long-term disease control.

High-dose glucocorticoids are the initial treatment once GCA is suspected. In a randomized trial, intravenous methylprednisolone given during the first 3 treatment days with oral prednisolone 40 mg/day was associated with faster glucocorticoid tapering, lower cumulative glucocorticoid exposure, and fewer relapses than placebo; patients with visual loss were excluded, so this trial does not establish intravenous treatment for acute visual ischemia.[11]

For long-term management, coordinate glucocorticoid tapering and relapse assessment with rheumatology. Targeted immunotherapy has changed GCA management, and current ACR guidance addresses glucocorticoid use and non-glucocorticoid immunosuppressive therapy, but regimen selection should account for ischemic phenotype, relapse history, cumulative steroid toxicity, and evidence of large-vessel disease.[2][11][20]

Monitor clinically for recurrent headache, jaw claudication, visual symptoms, diplopia, limb claudication, chest pain, and back pain; recurrence of ischemic symptoms requires urgent reassessment rather than routine outpatient taper adjustment. Permanent visual loss after treatment has been reported at approximately 2.2% in one longitudinal study and 2.8% in pooled literature, with risk concentrated in those with prior ischemic events and potentially during steroid tapering.[11]

In patients with large-vessel involvement, use longitudinal vascular imaging to evaluate stenotic and aneurysmal complications. Imaging is central to recognizing aortic and major branch-vessel disease, which can remain clinically silent until complications such as limb ischemia, chest or back pain, or aneurysm are present.[10][20]
- Initiation: start high-dose glucocorticoids when GCA is suspected; pursue diagnostic confirmation in parallel.[11][20][21]
- During taper: ask at each assessment about recurrent cranial ischemic symptoms and new limb, chest, or back symptoms.[10][11]
- At relapse or new ischemia: urgently reassess disease activity, ocular involvement, and vascular territory involvement; do not rely on inflammatory markers alone in cranial disease.[6][11]
- For established large-vessel disease: maintain imaging-based surveillance for stenosis and aortic aneurysmal complications.[10][20]

*Management phases in GCA.[10][11][20][21]*

| Phase | Clinical objective | Required action |
| --- | --- | --- |
| Initial suspected disease | Prevent irreversible visual and neurologic ischemia.[10][11] | Start high-dose glucocorticoids and arrange expedited ultrasound and/or TAB; add urgent ophthalmologic assessment for visual manifestations.[6][11][20][21] |
| Diagnostic extension | Define cranial versus large-vessel burden.[3][10] | Use temporal/axillary ultrasound for cranial assessment and CTA, MRA, MRI, or FDG-PET/CT for suspected extracranial disease.[3][10][13] |
| Taper and maintenance | Limit cumulative glucocorticoid exposure while detecting relapse.[11][20] | Coordinate rheumatology follow-up; assess recurrent ischemic symptoms and individualize steroid-sparing treatment decisions.[11][20] |
| Long-term surveillance | Detect stenosis and aortic aneurysmal complications.[10][20] | Repeat vascular assessment when symptoms or known large-vessel involvement warrant imaging surveillance.[10][20] |

## References
1. Giant cell arteritis - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/177?locale=no
2. British Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis | Practical Neurology — pn.bmj.com — https://pn.bmj.com/content/20/6/474
3. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care — rmdopen.bmj.com — https://rmdopen.bmj.com/content/9/2/e002970
4. NEJMcpc2002416_discussion_1 — www.nejm.org — https://www.nejm.org/cms/asset/d0b53b4b-787c-4d1d-9450-e7d8beebb2ee/assetFile/NEJMcpc2002416_discussion_1.html
5. Color Duplex Ultrasonography in the Diagnosis ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199711063371902
6. Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines | Eye — www.nature.com — https://www.nature.com/articles/s41433-020-1090-y
7. Current and Emerging Approaches to Imaging Large ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.124.015982
8. 2022 ACC/AHA Guideline for the Diagnosis and ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001106
9. Large Vessel Vasculitis Revisited: Mechanistic Insights and ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.125.047156
10. A new era for giant cell arteritis | Eye — www.nature.com — https://www.nature.com/articles/s41433-019-0608-7
11. Giant cell arteritis: reviewing the advancing diagnostics and management | Eye — www.nature.com — https://www.nature.com/articles/s41433-023-02433-y
12. Global epidemiology of vasculitis | Nature Reviews Rheumatology — www.nature.com — https://www.nature.com/articles/s41584-021-00718-8
13. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis _Free — academic.oup.com — https://academic.oup.com/rheumatology/article/59/3/e1/5714024?login=false
14. Altered Plasma Levels and Tissue Expression of Fibroblast ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25354
15. AB0739 PERFORMANCE OF THE 2022 AMERICAN COLLEGE OF RHEUMATOLOGY/EULAR CLASSIFICATION CRITERIA FOR GIANT CELL ARTERITIS IN A COHORT OF PATIENTS WITH SUSPICION OF HAVING GIANT CELL ARTERITIS - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0003496724656384
16. Current clinical practice trends in giant cell arteritis ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/imj.70319
17. Giant cell arteritis: an updated review — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1755-3768.2008.01314.x
18. Giant Cell Arteritis - Smith - 2014 - Wiley Online Library — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.12425
19. Giant cell arteritis: an updated review - Kawasaki - 2009 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2008.01314.x
20. 2021 American College of Rheumatology/Vasculitis ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24632
21. Diagnosis and management of giant cell arteritis: Major ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ceo.13897
22. Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.11226
23. American Headache Society 68th Annual Scientific Meeting ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.70117
24. All in the Family: A Curious Case of Aortopathy - McBride - 2022 — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24215

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.